Management of XXXX : role of @entity1773 .

@entity1 @entity146 @entity2358 @entity73 @entity4790 @entity51090 @entity2033 @entity1957 @entity74 @entity1773 @entity1154 @entity717 @entity18885 @entity14827
@entity2033 ( @entity2033 ) is an @entity14827 characterized by progressive @entity2358 , @entity146 , and @entity73 . The use of @entity1773 ( @entity18885 ), a specific inhibitor of vesicular @entity1154 transporter, is approved for @entity4790 in @entity2033 @entity1 . We aimed to review the medical literature concerning the efficacy and tolerability of @entity18885 in the treatment of @entity2033 @entity1 and to report our personal experience about @entity18885 use in a cohort of @entity2033 @entity1 . We searched PubMed (1960 to July 2010) using the following keywords: " @entity1773 " + " @entity2033 + @entity4790 ". We included randomized controlled trials, open-label trials, and retrospective studies. We excluded case reports and studies conducted on fewer than 20 @entity1 . In addition, we retrospectively evaluated 2 years' follow-up of @entity18885 treatment on motor and cognitive performances and functional abilities in 28 @entity2033 @entity1 , compared with 10 @entity1 treated by other neuroleptics ( @entity51090 ). Only four papers fulfilled the requested criteria. In the first study, which included 84 randomized outpatients, @entity18885 showed a significant improvement of @entity4790 compared with placebo. In the open-label study extension, @entity18885 confirmed its efficacy on @entity4790 , with a frequent occurrence of withdrawals due to side effects. In a retrospective study of long-term efficacy, 63 @entity1 under @entity18885 therapy for an average period of 34 months showed a stable effect on @entity4790 , despite a slight reduction of effect over time. In a telephone survey conducted on a total of 118 @entity1 affected by different @entity717 , @entity18885 showed the most favorable effect for the 28 included @entity2033 @entity1 . Our @entity2033 @entity1 showed a slight deterioration of motor performances over time that was nonsignificant compared with @entity18885 or @entity51090 treatments. Despite the fact that the global effect of @entity18885 seems positive in @entity2033 , more attention on evaluating symptomatic treatments for @entity73 as well as @entity1957 would alleviate this @entity74 until a neuroprotective treatment becomes available.
